Hudis, Clifford

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial

Basch, E., Deal, A. M., Kris, M. G., Scher, H. I., Hudis, C. A., Sabbatini, P., Rogak, L., Bennett, A. V., Dueck, A. C., Atkinson, T. M., et al. (2016) · Journal of Clinical Oncology

Cancer survivorship and careMobile Health and mHealth Applications

Cited by 2,593

Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment

Basch, E., Deal, A. M., Dueck, A. C., Scher, H. I., Kris, M. G., Hudis, C., & Schrag, D. (2017) · JAMA

Cancer survivorship and careMobile Health and mHealth Applications

Cited by 2,302

Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation

Iyengar, N. M., Gucalp, A., Dannenberg, A. J., & Hudis, C. A. (2016) · Journal of Clinical Oncology

Adipokines, Inflammation, and Metabolic DiseasesCancer Risks and Factors

Cited by 1,004

Developing a cancer‐specific geriatric assessment: A feasibility study

Hurria, A., Gupta, S., Zauderer, M., Zuckerman, E. L., Cohen, H. J., Muss, H., Rodin, M., Panageas, K. S., Holland, J. C., Saltz, L., et al. (2005) · Cancer

Frailty in Older AdultsNutrition and Health in Aging

Cited by 623

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 540

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

Modi, S., Stopeck, A., Linden, H., Solit, D., Chandarlapaty, S., Rosen, N., D'Andrea, G., Dickler, M., Moynahan, M. E., Sugarman, S., et al. (2011) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchHeat shock proteins research

Cited by 424

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · The Breast

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 338

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients

Scaltriti, M., Eichhorn, P. J., Cortés, J., Prudkin, L., Aura, C., Jiménez, J., Chandarlapaty, S., Serra, V., Prat, A., Ibrahim, Y. H., et al. (2011) · Proceedings of the National Academy of Sciences

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 337

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment

Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research

BRCA gene mutations in cancerBreast Cancer Treatment Studies

Cited by 307

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002

Winer, E. P., Hudis, C., Burstein, H. J., Chlebowski, R. T., Ingle, J. N., Edge, S. B., Mamounas, E. P., Gralow, J., Goldstein, L. J., Pritchard, K. I., et al. (2002) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesEstrogen and related hormone effects

Cited by 200

Menopause is a determinant of breast adipose inflammation

Iyengar, N. M., Morris, P. G., Zhou, X. K., Gucalp, A., Giri, D., Harbus, M. D., Falcone, D. J., Krasne, M. D., Vahdat, L. T., Subbaramaiah, K., et al. (2015) · Cancer Prevention Research

Adipokines, Inflammation, and Metabolic DiseasesEstrogen and related hormone effects

Cited by 106

Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers

Brown, K. A., Iyengar, N. M., Zhou, X. K., Gucalp, A., Subbaramaiah, K., Wang, H., Giri, D. D., Morrow, M., Falcone, D. J., Wendel, N. K., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism

Estrogen and related hormone effectsCancer Risks and Factors

Cited by 99

Frailty and Adherence to Adjuvant Hormonal Therapy in Older Women With Breast Cancer: CALGB Protocol 369901

Sheppard, V. B., Faul, L. A., Luta, G., Clapp, J. D., Yung, R. L., Wang, J. H.-Y., Kimmick, G., Isaacs, C., Tallarico, M., Barry, W. T., et al. (2014) · Journal of Clinical Oncology

Frailty in Older AdultsBreast Cancer Treatment Studies

Cited by 91

Therapeutic options for metastatic breast cancer

Morris, P. G., McArthur, H. L., & Hudis, C. A. (2009) · Expert Opinion on Pharmacotherapy

Breast Cancer Treatment StudiesHER2/EGFR in Cancer Research

Cited by 59

Estrogen protects against obesity-induced mammary gland inflammation in mice

Bhardwaj, P., Du, B., Zhou, X. K., Sue, E., Giri, D., Harbus, M. D., Falcone, D. J., Hudis, C. A., Subbaramaiah, K., & Dannenberg, A. J. (2015) · Cancer Prevention Research

Estrogen and related hormone effectsAdipokines, Inflammation, and Metabolic Diseases

Cited by 36